Britain approves Novavax COVID shot for 12-17 year-olds

National day of reflection to mark the 1 year anniversary of creation of The National Covid Memorial Wall, in London

(Reuters) - Britain's medicines regulator on Friday approved Novavax's COVID-19 vaccine for children aged between 12 and 17 years.

The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.

Britain in February cleared Novavax's two-dose vaccine, Nuvaxovid, for use in adults.

(Reporting by Sinchita Mitra in Bengaluru; editing by Krishna Chandra Eluri and Jason Neely)